Holigen
Portuguese medical cannabis cultivator operating under Akanda Corp, focused on EU-GMP production for European medical markets.
Holigen is a real Portuguese cultivation operation that became part of Akanda Corp in 2021. The site near Sintra was hyped during the early European medical cannabis boom as one of the continent's largest licensed grows. The reality has been messier: Akanda has faced repeated going-concern warnings, Nasdaq listing issues, and announced sales of Holigen assets. Treat any claim about current production capacity, licensing status, or output as something to verify directly with regulators before relying on it.
What it is
Holigen is a medical cannabis cultivation company with operations in Portugal, established to supply EU-GMP grade cannabis flower and extracts to European medical markets. Its main cultivation site is located in the Alentejo / Sintra region of Portugal, where the company has held licenses issued by INFARMED, Portugal's national medicines regulator [1]. The company was originally founded around 2017 and was an early entrant in Portugal's medical cannabis framework, which permits cultivation, manufacture, import and export of cannabis-based medicines under INFARMED authorisation [1][2].
Ownership and parent structure
Holigen was previously majority-owned by Australian cannabis company The Flowr Corporation, which acquired a controlling stake in 2019 [3]. In 2021, Holigen's assets were transferred into Akanda Corp, a newly formed company that listed on the Nasdaq in March 2022 under the ticker AKAN [4][5]. Akanda was formed through a combination of Holigen and Canmart, a UK-based medical cannabis importer [4]. Halo Collective, a North American cannabis operator, was a significant early shareholder in Akanda following the spin-out [5]. Ownership and corporate structure have shifted multiple times since; readers should check Akanda's most recent SEC filings for the current legal entity owning the Portuguese cultivation assets [6].
Market and category focus
Holigen's business model centres on bulk medical cannabis cultivation for export to regulated European medical markets — primarily Germany, the UK, and other EU jurisdictions that permit import of medical cannabis flower or extracts. Portugal is attractive for cultivators because of its climate, relatively low operating costs, and the existence of an INFARMED-regulated medical framework that allows export under EU-GMP standards [1][2]. Holigen has publicly described both outdoor and indoor/greenhouse cultivation footprints, though publicly reported figures about hectarage and output have varied considerably over the years and should not be taken at face value without regulatory confirmation.
Notable activities
Holigen does not sell consumer-facing branded products. Its output is bulk medical cannabis intended for pharmaceutical distribution channels. Publicly reported milestones include receipt of cultivation and manufacturing licenses from INFARMED [1], and announcements (via parent companies) of supply agreements with European medical distributors [3][4]. As with many companies in this sector, announced agreements have not always translated into sustained commercial shipments, and readers should distinguish press-release announcements from documented, ongoing supply.
Controversies and regulatory issues
Akanda, Holigen's parent, has faced significant corporate difficulties since its 2022 IPO. The company's share price collapsed sharply within months of listing, and Akanda has received multiple deficiency notices from Nasdaq related to minimum bid price and stockholders' equity requirements [6][7]. Akanda has disclosed going-concern doubts in financial filings and has announced restructuring, asset sales, and management changes [6]. In 2023, Akanda announced an agreement to sell Holigen-related assets, though the structure and completion of any such transactions should be verified in current filings [6]. Separately, journalism covering European medical cannabis has highlighted the gap between announced cultivation capacity at Portuguese sites (including Holigen's) and actual commercial output reaching pharmacies [8] [evidence:reported].
Availability and legal-market notes
Holigen does not sell to consumers. Any cannabis ultimately reaching patients via Holigen-grown material would be dispensed through licensed pharmacies in countries that permit medical cannabis on prescription (e.g. Germany, UK private clinics, Portugal under specific authorisation) [2]. There is no retail Holigen brand. Recreational sale of cannabis remains illegal in Portugal despite the country's well-known decriminalisation of personal possession, which is a separate legal regime from medical cultivation and export [2].
What to verify before relying on brand claims
Before treating any claim about Holigen as current fact, check: (1) Holigen's INFARMED licensing status directly via INFARMED's published licensee lists [1]; (2) Akanda Corp's most recent SEC filings (10-K, 20-F, 6-K) for current ownership of the Portuguese assets and going-concern status [6]; (3) whether announced supply agreements have resulted in disclosed revenue rather than only press releases; (4) Nasdaq listing status of the parent, given the history of deficiency notices [7]. Profile last checked: 2024. Cannabis-industry corporate structures change quickly and this article may lag current events.
Sources
- Government INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde. Medicamentos, preparações e substâncias à base da planta da canábis para fins medicinais.
- Government Assembleia da República. Lei n.º 33/2018, de 18 de julho - Utilização de medicamentos, preparações e substâncias à base da planta da canábis para fins medicinais.
- Reported Marijuana Business Daily. 'Flowr completes Holigen acquisition, eyes European medical cannabis market.' 2019.
- Reported MJBizDaily. 'Akanda completes IPO on Nasdaq, raising $16 million.' March 2022.
- Government U.S. Securities and Exchange Commission. Akanda Corp Form F-1 Registration Statement, filed 2021-2022.
- Government U.S. Securities and Exchange Commission. Akanda Corp filings (20-F, 6-K).
- Reported Business of Cannabis. 'Akanda receives Nasdaq deficiency notice.' 2023.
- Reported Business of Cannabis / Prohibition Partners coverage of Portuguese medical cannabis cultivation gap between announced capacity and commercial output, 2022-2023.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Tilray Portugal — A medical cannabis cultivation and processing campus in central Portugal owned by Tilray B...